Treatment of nausea and vomiting during pregnancy —a cross-sectional study among 712 Norwegian women
- 1.1k Downloads
The purposes of this study were to investigate the treatments used for nausea and vomiting of pregnancy (NVP) according to NVP severity among Norwegian women and to assess whether maternal characteristics and attitudes were related to the use of pharmacological treatment of NVP.
This is a cross-sectional Web-based study. Pregnant women and mothers with children ≤1 year of age were eligible to participate. Data were collected through an anonymous online questionnaire accessible from November 10th, 2014 to January 31st, 2015.
In total, 712 women were included in the study, of which 62 (8.7 %), 439 (61.7 %) and 210 (29.5 %) had mild, moderate and severe NVP, respectively, according to the Pregnancy-Unique Quantification of Emesis (PUQE) classification. A total of 277 (38.9 %) women had used one or more antiemetics, of which meclizine, closely followed by metoclopramide, was the most commonly used. Different drug utilisation patterns were found between the groups of women with mild, moderate and severe NVP. Many with moderate or severe symptoms did not use any pharmacological treatment (70.2 and 32.9 %, respectively). Sick leave was given without initiating medical treatment in 266 (62.1 %) women. The women’s beliefs about medicines had an important impact on their use of medicines for NVP.
A large proportion of women suffered from moderate to severe symptoms of NVP, many of whom did not receive any pharmacological treatment. Many women, who had been on sick leave due to NVP, were not prescribed medicines.
KeywordsMorning sickness Hyperemesis gravidarum Pregnancy Drug therapy Meclizine Metoclopramide
We thank the providers of the websites for contributions in the recruitment phase, and all the women who participated in the study. KH received funding for her PhD project from The Norwegian Research Council (Grant no. 195475).
KH, LH, GCH and HN conceived and designed the study. AS collected the data. KH performed the statistical analyses and drafted the manuscript. All authors contributed to the interpretation of the results and to the final manuscript. All authors read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 9.Smith J, Refuerzo J, Ramin S (2014) Treatment and outcome of nausea and vomiting of pregnancy. UpToDateGoogle Scholar
- 10.National Collaborating Centre for Women’s and Children’s Health (2008) Antenatal care: routine care for the healthy pregnant woman. National Institute for Health and Clinical Excellence (NICE). http://www.nice.org.uk/guidance/cg62/evidence/full-guideline-corrected-june-2008-196748317. Accessed 19 March 2015
- 12.Sosial og helsedirektoratet [The Norwegian Directorate of Health and Social Affairs] (2005) Nasjonale faglige retningslinjer: Retningslinjer for svangerskapsomsorgen [A National Clinical Guideline for antenatal care]. 2005 ednGoogle Scholar
- 13.Norsk Legemiddelhåndbok [Norwegian Medicines Handbook] (2015) http://legemiddelhandboka.no/Terapi/søker/+%2Bsvangerskapskvalme/19493. Accessed 09 April 2015
- 14.Norsk gynekologisk forening [The Norwegian Society of Obstetrics and Gynecology] (2014) Veileder i fødselshjelp [Obstetric guidelines issued by The Norwegian Society of Obstetrics and Gynaecology (NGF)]Google Scholar
- 15.BMJ Best Practice (2015) Nausea and vomiting in pregnancy. http://bestpractice.bmj.com/best-practice/monograph/999.html
- 16.Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62(6):385–392. doi: 10.1002/1096-9926(200012)62:6<385::Aid-Tera5>3.0.Co;2-Z CrossRefPubMedGoogle Scholar
- 25.The Norwegian Welfare and Labour Administration (2011) Sickness benefits for employees. The Norwegian Welfare and Labour Administration. https://www.nav.no/en/Home/Benefits+and+services/Relatert+informasjon/Sickness+benefits+for+employees.283831.cms. Accessed 19 Aug 2015
- 26.The Norwegian Directorate of Health (2014) Svangerskapskontroller [pregnancy consultations]. helsenorge.no. https://helsenorge.no/gravid/svangerskapskontroller. Accessed 27 Aug 2015
- 30.Birkeland E, Stokke G, Tangvik RJ, Torkildsen EA, Boateng J, Wollen AL, Albrechtsen S, Flaatten H, Trovik J (2015) Norwegian PUQE (pregnancy-unique quantification of emesis and nausea) identifies patients with hyperemesis gravidarum and poor nutritional intake: a prospective cohort validation study. PLoS One 10(4):e0119962CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Medical Birth Registry of Norway - Statistics (2015) http://mfr-nesstar.uib.no/mfr/. Accessed 08 July 2015
- 34.StatBank Norway, Table 08921: Persons 16 years and older, by sex, age and level of education. Numbers and per cent (C) (2015) Statistics Norway. https://www.ssb.no/en/statistikkbanken. Accessed 08 July 2015
- 38.European Medicines Agency (2013) European Medicines Agency recommends changes to the use of metoclopramide. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/07/WC500146614.pdf. Accessed 19 March 2015
- 39.Summary of product characteristics - Stemetil 5 mg tablets (2014) The Norwegian Medicines Agency. http://www.legemiddelverket.no/_layouts/Preparatomtaler/Spc/0000-03629.pdf?id=25072014142813. Accessed 1 Oct 2015
- 40.Summary of product characteristics - Chlorpromazine 50 mg tablets (2014) The electronic medicines compendium (eMC). http://www.medicines.org.uk/emc/medicine/29499. Accessed 1 Oct 2015
- 41.FDA (2010) Safety information - Reglan (metoclopramide) tablets, ODT (Orally disintegrating tablets), and injection. FDA. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm170934.htm. Accessed 08 July 2015
- 43.Andersen JT, Jimenez-Solem E, Andersen NL, Poulsen HE (2013) Abstract 25, pregnancy session 1. Ondansetron use in early pregnancy and the risk of congenital malformations – a register based nationwide cohort study. International Society of Pharmaco-Epidemiology, MontrealGoogle Scholar
- 45.Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA, National Birth Defects Prevention S (2012) Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defect Res Part A Clin Mol Teratol 94(1):22–30. doi: 10.1002/bdra.22865 CrossRefGoogle Scholar
- 71.Norwegian media barometer - Table: 04519: percentage internet users and minutes used for internet an average day, by sex and education (2015) Statistics Norway https://www.ssb.no/statistikkbanken/selecttable/hovedtabellHjem.asp?KortNavnWeb=medie&CMSSubjectArea=kultur-og-fritid&PLanguage=1&checked=true. Accessed 08 July 2015